Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell
GlaxoSmithKline has struck a deal to buy Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures. Sitari, a preclinical-stage biotech, is developing inhibitors of the TG2 enzyme as treatments for the autoimmune digestive disorder celiac disease. GSK and Avalon came together to found Sitari in 2013. Sitari raised a $10 million series A round in the same year and then worked within Avalon’s COI Pharmaceuticals incubator to develop intellectual property in-licensed from Stanford University’s Chaitan Kholsa. Having established a preclinical program, Sitari has now generated enough evidence to persuade GSK to acquire its operations.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
